The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study단일 의료 시스템에서 의료 종사자들 사이에서 BNT162b2 백신 접종 후 SARS-CoV-2 스파이크 단백질에 대한 부작용과 면역 반응 사이의 연관성: 전향적 관찰 코호트 연구Observational Study Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, SARS, 임상, 진단, [키워드] administration Adverse Adverse reaction Anti-spike IgG antibody anti-spike IgG level Antibody titer association Asthma BNT162b2 BNT162b2 vaccine conducted COVID-19 Cutoff determine Factor first dose healthcare healthcare worker help humoral humoral immune response Humoral response IgG IgG level immune response information Local majority median median age mRNA mRNA vaccine of BNT162b2 participant Participants prospective observational cohort reaction recipients recruited reported SARS-CoV-2 anti-spike IgG SARS-CoV-2 spike protein second dose significantly higher systemic adverse reactions Systemic adverse reactions. systemic reaction vaccination Vaccine was collected were measured with COVID-19 women [DOI] 10.1080/21645515.2022.2048559 PMC 바로가기 [Article Type] Observational Study
Viral keratitis after the second and third doses of inactivated COVID-19 vaccination: A case reportArticle Published on 2022-11-302022-11-15 Journal: Human vaccines & immunotherapeutics [Category] 진단, [키워드] Adverse reaction benefit Case report coronavirus disease COVID-19 COVID-19 vaccination COVID-19 vaccines dose drugs eye immunization inactivated Inactivated vaccine individual knowledge ocular physician potential risk receiving reported returned SARS-CoV-2 Symptom the patient Treatment vaccination Viral keratitis viral keratitis. virus visual acuity [DOI] 10.1080/21645515.2022.2090177 PMC 바로가기
COVID-19 vaccine associated transverse myelitis-Evusheld as an option when vaccination is not recommended due to severe adverse eventsCOVID-19 백신 관련 횡단 척수염-심각한 부작용으로 인해 백신 접종이 권장되지 않는 경우 옵션으로 EvusheldArticle Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] administer administration adverse event Adverse reaction antibody Autoimmune COVID-19 COVID-19 vaccine determine individual Inflammation mechanism MHRA Moderna mRNA vaccine monoclonal antibody Patient precluded prophylactic therapy PROTECT receiving resulting Safe SARS-COV-2 infection severe adverse event spike-protein therapy U.S. FDA vaccination [DOI] 10.1080/21645515.2022.2068338 PMC 바로가기 [Article Type] Article
Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [ComirnatyⓇ])Article Published on 2022-11-012022-11-15 Journal: International Journal of Infectious Diseases [Category] SARS, 진단, [키워드] acute exacerbation Adverse Adverse reaction Asthma BNT162b2 center Control COVID-19 vaccine dose effective eligible eosinophilia eosinophils Hospitalization individuals life-threatening Messenger RNA Patient Pfizer-BioNTech prevention receiving repeated risk factor SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccine, Acute asthma exacerbation sensitization Sensitization. the patient the SARS-CoV-2 vaccination Vaccine [DOI] 10.1016/j.ijid.2022.09.019 PMC 바로가기
Cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experienceArticle Published on 2022-11-012022-11-15 Journal: Journal of the European Academy of Dermatology and [Category] COVID19(2023년), SARS, 진단, [키워드] Adverse reaction booster Cutaneous multicentre SARS-CoV-2 vaccine [DOI] 10.1111/jdv.18386 PMC 바로가기
Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of viewArticle Published on 2022-10-012022-11-15 Journal: Inflammopharmacology [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] Adverse reaction Antiviral antiviral drug antivirals association COVID-19 COVID-19 positive patients drug-resistant drugs effective Efficacy effort Evidence Hospitalization Hypothesis manuscript monotherapy New reducing Remdesivir risk safety profile SARS-CoV-2 SARS-CoV-2 drug SARS-COV-2 infection SARS-CoV-2. therapy Treatment variants with COVID-19 [DOI] 10.1007/s10787-022-01055-2 PMC 바로가기
A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and OlderArticle Published on 2022-10-012022-11-16 Journal: Journal of community health [Category] COVID19(2023년), SARS, 변종, [키워드] Active surveillance Adverse adverse event adverse events Adverse reaction Adverse reactions B.1.1.529 B.1.617.2 booster booster dose Comirnaty COVID-19 COVID-19 booster vaccination COVID-19 vaccination Delta described dose enrolled events fatigue female Fever Frequency injection Italy lack Local malaise Mild moderate Moderna mRNA mRNA vaccines occurred Occurrence Older omicron outcome Pain participant Pfizer/BioNTech questionnaire reaction recipient reported Safety significantly Spikevax. stratified Surveillance vaccination Vaccine variants vomiting was used Year [DOI] 10.1007/s10900-022-01112-5 PMC 바로가기
Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteersArticle Published on 2022-09-292022-11-15 Journal: Scientific Reports [Category] 진단, [키워드] 1.26 Adverse reaction affecting age anti-S anti-S antibody anti-S IgG anti-Spike IgG antibody Antibody titer Antibody titers BNT162b2 vaccine conducted COVID-19 vaccination cross-sectional dose Effect elapsed Factor Factors female females Gender healthy healthy volunteer identify IgG antibody titer immunosuppressants immunosuppressive IQR Japanese magnitude median age mRNA mRNA-1273 mRNA-1273 vaccine Multiple positive questionnaire SARS-COV-2 infection significantly smoking tested the vaccine therapy vaccination Vaccine Volunteer [DOI] 10.1038/s41598-022-20747-x PMC 바로가기
Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort studyArticle Published on 2022-09-162022-11-15 Journal: Vaccine [Category] SARS, 진단, [키워드] administration Adverse reaction All participant anti-SARS-CoV-2 approved BBIBP-CorV can be used China Complete control group COVID-19 COVID-19 vaccine Cytopathic effect dose doses first dose geometric mean concentration geometric mean titer GMCs GMTs healthy immune persistence immunogenicity Immunoglobulin inactivated Inactivated vaccine Mild mitigate moderate NAb National not different not significantly different observation Observational cohort study Pragmatic regimens replacement Replacement vaccine Safety safety profile Safety. SARS-CoV-2 strain second dose sera severity Standard subject vaccination WHO [DOI] 10.1016/j.vaccine.2022.08.037 PMC 바로가기
Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiencyArticle Published on 2022-09-142022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술, [키워드] activity Adverse reaction analyzed Anti-SARS-CoV-2 S antibody Antibody Response Autoimmune Autoimmune diseases B-lymphocytes Cell Cohort cohort of patient comparable Course COVID-19 COVID-19 vaccination CVID deficiency detect Disease activity dysfunction effective Efficacy and safety Elecsy flow cytometry healthy control humoral humoral immune response Hypogammaglobulinemia IFN-gamma immune system Immunity immunization immunoassay immunodeficiency immunoglobulin replacement therapy in healthy individuals increased risk individual Interferon-gamma lymphocyte neutralization Patient Phenotyping pneumococcal provide reactogenicity receptor Safe SARS-COV-2 infection selective Seven subjects Support syndrome T cell response T-lymphocites the disease triggering underlying disease vaccination vaccination. vaccine response Vero E6 Virus neutralization was performed well X-linked agammaglobulinemia XLA [DOI] 10.3389/fimmu.2022.974987 PMC 바로가기